The global adrenocorticotropic hormone (ACTH) market was valued at US$ 1.3 Bn in 2020 and is projected to reach US$ 1.91 Bn by 2031, expanding at a compound annual growth rate (CAGR) of 3.9% during the forecast period from 2021 to 2031. The steady growth trajectory reflects increasing clinical applications of ACTH therapies and a rising prevalence of endocrine and neurological disorders worldwide.

The market’s moderate but stable expansion is supported by strong demand across therapeutic areas such as nephrotic syndrome, multiple sclerosis, and infantile spasms, alongside advancements in hormone-based treatments.

→Discover Market Opportunities – Request Your Sample Copy Now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=76241

Market Overview

Adrenocorticotropic hormone (ACTH), also known as corticotropin, plays a vital role in regulating cortisol production in the adrenal glands. It is widely used in diagnostic testing and therapeutic applications, particularly for adrenal insufficiency and autoimmune diseases.

The COVID-19 pandemic significantly influenced healthcare delivery patterns. Understanding care patterns of high-risk patients gained importance as healthcare systems adapted to unprecedented pressure. Manufacturers in the ACTH market responded by strengthening supply chains and collaborating with urgent care centers, pharmacy-based retail clinics, and workplace clinics to maintain continuity of care.

Telehealth services emerged as a key business model, especially for non-elderly patients with mild symptoms or at risk of COVID-19. These services enhanced access to care while reducing the burden on emergency departments.

Additionally, ACTH is increasingly being used for screening patients with suspected adrenocortical insufficiency, with online diagnostic accessibility improving patient reach and early detection.

Key Market Growth Drivers

One of the primary drivers of the ACTH market is the rising prevalence of chronic and endocrine disorders, including Cushing’s disease, Addison disease, hypopituitarism, and multiple sclerosis. ACTH blood tests, often used alongside cortisol tests, are essential for diagnosing and monitoring these conditions.

The increasing incidence of stress and anxiety disorders is another contributing factor. Elevated stress levels are associated with increased ACTH secretion, indirectly boosting demand for diagnostic and therapeutic solutions.

Furthermore, ACTH is widely used in treating:

• Infantile spasms (prevalence: 1.5–2.0 per 10,000 children under 10 years)
• Nephrotic syndrome
• Rheumatology-related conditions
• Ankylosing spondylitis

The expansion of applications across multiple indications significantly enhances market potential.

Another key driver is the increase in R&D investments aimed at developing advanced therapies. Innovations such as continuous subcutaneous hydrocortisone infusion and CRH1 receptor antagonists (e.g., pexacerfont) are opening new therapeutic avenues.

Analysis of Key Players – Key Player Strategies

The ACTH market is highly consolidated, with a few dominant players holding a significant share. Major companies include:

• Mallinckrodt plc
• Pfizer, Inc.
• Novartis AG
• Merck KGaA
• Ferring B.V.
• Avantor, Inc.
• Viatris, Inc.
• Hikma Pharmaceuticals plc

Strategic Focus Areas:

• Product Portfolio Expansion: Companies are enhancing their ACTH-based drug offerings to cover multiple indications.
• Regulatory Approvals: Continuous efforts to secure approvals for new indications and updated labeling.
• Partnerships & Collaborations: Strategic alliances to develop and commercialize new corticotropin formulations.
• Acquisitions: Strengthening market position through mergers and acquisitions (e.g., Avantor’s acquisition of Ritter GmbH).
• R&D Investment: Focus on innovative drug delivery systems and next-generation hormone therapies.

Market Challenges & Opportunities

Challenges

A major restraint in the ACTH market is the high cost of treatment. ACTH therapies are significantly more expensive than alternatives:

• ACTH injections can cost over US$ 30,000 per vial
• Prices increased dramatically from US$ 50 in 2000 to over US$ 34,000 per vial in 2017

Such pricing limits accessibility, especially for long-term treatments required for chronic conditions.

Additionally, side effects of ACTH, including bone loss, muscle weakness, indigestion, back pain, and hyperpigmentation, raise concerns among patients and healthcare providers.

Diagnostic challenges, such as abnormal test results due to medication interference, also hinder accurate disease detection.

Opportunities

Despite these challenges, several growth opportunities exist:

• Rising awareness of rare endocrine disorders
• Expansion of telehealth and digital diagnostics
• Development of cost-effective treatment alternatives
• Increasing focus on personalized medicine
• Research into ectopic ACTH production and related syndromes

Conditions like ectopic ACTH syndrome (EAS) and non-neoplastic hypercortisolemia (NNH) are opening new avenues for targeted therapies.

→Explore Strategies & Trends – Request Full Report Access – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=76241

Key Player Strategies

Key players are adopting multi-dimensional strategies to sustain growth:

• Awareness Programs: Educating clinicians and patients on managing ACTH side effects
• Supply Chain Optimization: Ensuring uninterrupted drug availability during crises such as COVID-19
• Digital Integration: Leveraging telemedicine and online diagnostics
• Innovation in Drug Delivery: Developing infusion-based therapies and advanced formulations
• Global Expansion: Strengthening presence in emerging markets

Recent Developments

• In July 2021, Mallinckrodt announced inclusion of Acthar Gel (repository corticotropin injection) in New European Respiratory Society (ERS) Treatment Guidelines for patients with pulmonary sarcoidosis
• In June 2021, Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies, and applied materials industries, announced it has completed its previously announced acquisition of Ritter GmbH and its affiliates
• In March 2021, Mallinckrodt announced the U.S. Food and Drug Administration (FDA) approval for the updated Acthar Gel (repository corticotropin injection) label
• In August 2020, Upsher-Smith Laboratories, LLC (Upsher-Smith) and AmbioPharm, Inc. (AmbioPharm) announced that the companies entered into a partnership agreement to develop and market Corticotropin Injection in the U.S.
• In China, a research study on the role of corticotropin releasing factor in the neuroimmune mechanisms of depression is underway

Investment Landscape and ROI Outlook

The ACTH market presents a moderate yet stable ROI profile, driven by consistent demand in chronic disease management. Investment is particularly strong in:

• Biopharmaceutical R&D
• Advanced drug delivery technologies
• Rare disease therapeutics

Although high treatment costs pose a barrier, the premium pricing model ensures strong margins for manufacturers, making the market attractive for long-term investments.

Emerging economies, especially in Asia Pacific, are expected to offer high-growth opportunities due to improving healthcare infrastructure and rising disease awareness.

Market Segmentations

By Source

• Natural
• Synthetic

By Indication

• Rheumatology
• Neurology
• Nephrotic Syndrome
• Ophthalmology
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Sales

By Region

• North America: Dominated the market in 2020 due to advanced healthcare systems and high treatment adoption
• Europe: Strong growth supported by regulatory approvals and R&D investments
• Asia Pacific: Fastest-growing region driven by increasing patient population and healthcare access
• Latin America & Middle East & Africa: Emerging markets with untapped potential

Why Buy This Report?

• Comprehensive analysis of market size, trends, and forecasts up to 2031
• Detailed insights into drivers, restraints, and opportunities
• In-depth profiling of key players and competitive landscape
• Coverage of recent developments and strategic initiatives
• Regional and segment-wise analysis for targeted decision-making
• Reliable data for investment planning and business expansion

FAQs

1. What is the total market size of the ACTH market?

The ACTH market was valued at US$ 1.3 Bn in 2020 and is expected to exceed US$ 1.91 Bn by 2031.

2. What is the projected growth rate of the market?

The market is anticipated to grow at a CAGR of 3.9% during the forecast period from 2021 to 2031.

3. What are the key factors driving market growth?

Key drivers include rising prevalence of chronic diseases, increasing R&D investments, and expanding therapeutic applications.

4. Which region dominates the ACTH market?

North America currently leads the market and is expected to maintain its dominance.

5. What challenges does the market face?

High treatment costs, side effects of ACTH therapy, and diagnostic limitations are the major challenges impacting market growth.

Buy Full Report Now: https://www.transparencymarketresearch.com/checkout.php?rep_id=76241&ltype=S

→Explore Latest Research Reports by Transparency Market Research:

Mexico Medical Cannabis Market: https://www.transparencymarketresearch.com/mexico-medical-cannabis-market.html

Hydroxychloroquine Drugs Market: https://www.transparencymarketresearch.com/hydroxychloroquine-drugs-market.html

Live Biotherapeutics Market: https://www.transparencymarketresearch.com/live-biotherapeutics-market.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.